Acamprosate: A Review of Its Use in Alcohol Dependence
The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Abstract
Acamprosate (Campral(®), Aotal(®), Regtect(®)) is one of a limited number of pharmacological treatment options approved as an adjunct to psychosocial interventions to facilitate the maintenance of abstinence in alcohol-dependent patients. It has been used in Europe, the USA and other countries for many years and was recently approved for this indication in Japan. In several randomized, double-blind, placebo-controlled trials (without active comparators), acamprosate in conjunction with psychosocial therapy for 3-12 months was generally significantly better than placebo plus psychosocial interventions in improving various key outcomes, including the proportion of patients who maintained complete abstinence from alcohol (complete abstinence rate), the mean cumulative abstinence duration, the percentage of alcohol-free days and the median time to first drink. Acamprosate as an adjunct to psychosocial interventions also demonstrated efficacy in some randomized, active-comparator trials of similar duration. Although results were not always consistent across individual trials, overall findings were generally favourable for acamprosate in a recent meta-analysis, which showed that alcohol-consumption outcomes were similarly improved with acamprosate or naltrexone. Acamprosate is generally well tolerated, has a low propensity for drug interactions and may be used without dosage adjustment in patients with mild to moderate hepatic impairment, although dosage adjustments or contraindica…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Anton, R. F., O’Malley, S. S., Ciraulo, D. A., Cisler, R. A., Couper, D., Donovan, D. M., Gastfriend, D. R., Hosking, J. D., Johnson, B. A., LoCastro, J. S., et al. (2006) · JAMA · doi:10.1001/jama.295.17.2003 · Cited by 1,930 · cited 4×
“In the largest trial (COMBINE), 1383 patients from 11 US sites were randomized to nine possible treatment groups, of which four included medication without a combined behavioural intervention (CBI), four included medication with CBI and one included only CBI (no pills) [42].”
BackgroundMethodResultInfluentialJonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923 · cited 5×
“Overall, results were generally favourable for acamprosate in a recent systematic review and meta-analysis of pharmacotherapy for alcohol use disorders in outpatient settings that included 22 placebo-controlled trials with acamprosate, 44 with naltrexone and 4 with disulfiram [28].”
InfluentialThe clock gene Per2 influences the glutamatergic system and modulates alcohol consumption
Spanagel, R., Pendyala, G., Abarca, C., Zghoul, T., Sanchis-Segura, C., Magnone, M. C., Lascorz, J., Depner, M., Holzberg, D., Soyka, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1163 · Cited by 594 · cited 1×
“Acamprosate has been shown to attenuate hyperglutamatergic activity and reduce ethanol consumption in mice that were drinking excessive quantities of ethanol [17, 18], and it reduced glutamate levels (assessed by magnetic resonance spectroscopy) in the brains of alcohol-dependent patients who had been detoxified [19].”
BackgroundHelping Patients Who Drink Too Much: A Clinician's Guide: (495492006-001)
US Department of Health and Human Services; National Institutes of Health; National Institute on Alcohol Abuse and Alcoholism (2005) · PsycEXTRA Dataset · doi:10.1037/e495492006-001 · Cited by 589
Relapse Prevention by Acamprosate: Results From a Placebo-Controlled Study on Alcohol Dependence
Sass, H. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830080023006 · Cited by 479 · cited 3×
“45 days; p-value not reported), which was also a co-primary endpoint [39].”
BackgroundMaisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400 · cited 2×
“Most were also double-blind, placebocontrolled trials [42, 43, 45, 47, 48], although two studies used an open-label design, in part, because patients in one of the treatment arms received disulfiram, and patients’ awareness that they are taking disulfiram is an important factor in its effectiveness [44, 46].”
BackgroundResultHelping patients who drinks too much. A Clinician’s Guide
Agabio, R., Fantozzi, F., & Tossicodipendenze, C. E. D. R. M. D. (2006) · UNICA IRIS Institutional Research Information System (University of Cagliari) · Cited by 391
Comparison of acamprosate and placebo in long-term treatment of alcohol dependence
Whitworth, A. B., Oberbauer, H., Fleischhacker, W. W., Lesch, O. M., Walter, H., Nimmerrichter, A., Platz, T., Fischer, F., & Potgieter, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91682-7 · Cited by 320 · cited 3×
“tive abstinence duration at the end of follow-up [38, 40].”
Background
Cited by
Analysis of US FDA-Approved Drugs Containing Sulfur Atoms
Scott, K. A., & Njardarson, J. T. (2018) · Topics in Current Chemistry · doi:10.1007/s41061-018-0184-5 · Cited by 1,036
Volkow, N. D., & Blanco, C. (2023) · World psychiatry · doi:10.1002/wps.21073 · Cited by 503
Don’t stress about CRF: assessing the translational failures of CRF1antagonists
Spierling, S. R., & Zorrilla, E. P. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4556-2 · Cited by 170
“analogously, show some efficacy to mitigate alcohol use disorders (see Stevenson et al. 2015; Keating 2013; Rösner et al. 2010; Plosker 2015; but see Palpacuer et al. 2015).”
Medications for alcohol use disorders: An overview
Akbar, M., Egli, M., Cho, Y.-E., Song, B.-J., & Noronha, A. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.007 · Cited by 96
“Thus, the use of acamprosate as an adjunct to psychosocial interventions in alcohol-dependent patients provides modest but potentially valuable improvements in alcohol-consumption outcomes (Plosker, 2015).”
Review article: pharmacotherapy for alcohol dependence – the why, the what and the wherefore
Goh, E. T., & Morgan, M. Y. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13965 · Cited by 87
Metadata
- Authors
- Plosker, G. L.
- Affiliations
- Springer Nature (Germany) (DE)
- Corresponding author
- Plosker, Greg L.
- Venue
- Drugs
- Published
- 2015-06-18
- Volume
- 75
- Issue
- 11
- Pages
- 1255-1268
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W637714516
- Semantic Scholar
- 7fbe0bfe4c7b939d7fb97f13c2f968cecf8b6072
- Cited by
- 65
- References
- 67
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 8 · 2023: 9 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 7 · 2018: 7 · 2017: 5 · 2016: 2
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- acamprosate, alcoholism, alcoholism treatment, pharmacotherapy, psychosocial interventions, abstinence maintenance, naltrexone, drug interactions, liver dysfunction, renal dysfunction, tolerability
- MeSH terms
- Acamprosate, Alcohol Deterrents, Alcoholism, Animals, Dose-Response Relationship, Drug, Drug Interactions, Humans, Taurine, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acamprosate: A Review of Its Use in Alcohol Dependence. https://app.cochat.ai/papers/10.1007/s40265-015-0423-9
- The paper
- Plosker, G. L. (2015). Acamprosate: A Review of Its Use in Alcohol Dependence. Drugs. https://doi.org/10.1007/s40265-015-0423-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.